SSTR2 and neoplasm: Accordingly, we selected the dually implantedHCT116-SSTR2/WT xenograft model and a dose of 2 nmol per mouse, whichwe previously used to evaluate our first-generation agent.17 We injected the fluorescent conjugates in miceand performed in vivo NIRF imaging at 1 and 3 h p.i.,followed by ex vivo imaging of resected tissues.Consistent with our published results,17 clear tumor delineation was not possible with MMC(IR800)-TOC ateither time point due to high background fluorescence (Figure 2A, Supporting Figures 7 and 8).